Latest news
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’ - StocktwitsStocktwits · Mon, 10 Aug 2026 13:27:16 GMTMoonLake Q2 Results: EPS of $(0.84) beats estimates - scanx.tradescanx.trade · Mon, 10 Aug 2026 11:52:24 GMTMoonLake Immunotherapeutics 2Q 2026: Net loss $(61.8)M, EPS $(0.84) — 10-Q Summary - TradingViewTradingView · Mon, 10 Aug 2026 11:51:01 GMTMoonLake Immunotherapeutics (MLTX) deepens loss but ends H1 2026 with $537M cash and key Phase 3 wins - stocktitan.netstocktitan.net · Mon, 10 Aug 2026 11:47:01 GMTMoonLake reports positive Phase 3 PsA data and $537 million cash - Quiver QuantitativeQuiver Quantitative · Mon, 10 Aug 2026 11:20:00 GMTMoonLake Immunotherapeutics AG - Via RitzauVia Ritzau · Mon, 10 Aug 2026 11:00:00 GMTMLTX Stock Jumps Over 10% Overnight As Spine Drug Trial Win Sets Stage For Investor Day Showdown - StocktwitsStocktwits · Sat, 08 Aug 2026 12:08:41 GMTMLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts - StocktwitsStocktwits · Sat, 08 Aug 2026 10:45:41 GMT